Open access
Sep 2026
Impact of Neoadjuvant Approach and Tumor Response on Survival in Pancreatic Adenocarcinoma
Neoadjuvant therapy for pancreatic adenocarcinoma (PDAC) has evolved from single‐agent to multi‐agent approaches, largely informed by metastatic disease studies demonstrating improved survival; albeit at the price of increased toxicity. It remains unclear how response to varied neoadjuvant regimens impact survival. We...
M. Suraju, Brian C. Longbottom, Jasmine Peterson et al.
· Journal of Surgical Oncology · 0 citations